0001070081-19-000061.txt : 20191226 0001070081-19-000061.hdr.sgml : 20191226 20191226172432 ACCESSION NUMBER: 0001070081-19-000061 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191223 FILED AS OF DATE: 20191226 DATE AS OF CHANGE: 20191226 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Souza Marcio CENTRAL INDEX KEY: 0001707657 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35969 FILM NUMBER: 191311144 MAIL ADDRESS: STREET 1: C/O PTC THERAPEUTICS, INC. STREET 2: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PTC THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001070081 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043416587 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080-2449 BUSINESS PHONE: 9082227000 MAIL ADDRESS: STREET 1: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080-2449 FORMER COMPANY: FORMER CONFORMED NAME: PTC THERAPEUTICS INC DATE OF NAME CHANGE: 19980909 4 1 wf-form4_157739905265156.xml FORM 4 X0306 4 2019-12-23 0 0001070081 PTC THERAPEUTICS, INC. PTCT 0001707657 Souza Marcio C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 0 1 0 0 Chief Operating Officer Common Stock 2019-12-23 4 S 0 6000 48.322 D 53035 D Common Stock 2019-12-23 4 S 0 14814 49.141 D 38221 D Common Stock 2019-12-23 4 M 0 30000 12.53 A 68221 D Common Stock 2019-12-23 4 S 0 8729 48.321 D 59492 D Common Stock 2019-12-23 4 S 0 21271 49.14 D 38221 D Common Stock 2019-12-23 4 M 0 15881 11.23 A 54102 D Common Stock 2019-12-23 4 S 0 8877 48.58 D 45225 D Common Stock 2019-12-23 4 S 0 7004 49.319 D 38221 D Common Stock 2019-12-23 4 M 0 30000 18.01 A 68221 D Common Stock 2019-12-23 4 S 0 11332 48.431 D 56889 D Common Stock 2019-12-23 4 S 0 18668 49.19 D 38221 D Common Stock 2019-12-23 4 M 0 6250 12.92 A 11288 I By Spouse Common Stock 2019-12-23 4 S 0 6250 48.80 D 5038 I By Spouse Stock Option (Right To Buy) 12.53 2019-12-23 4 M 0 30000 12.53 D 2027-05-30 Common Stock 30000.0 0 D Stock Option (Right To Buy) 11.23 2019-12-23 4 M 0 15881 11.23 D 2027-01-02 Common Stock 15881.0 7219 D Stock Option (Right To Buy) 18.01 2019-12-23 4 M 0 30000 18.01 D 2028-01-02 Common Stock 30000.0 45000 D Stock Option (Right To Buy) 12.92 2019-12-23 4 M 0 6250 12.92 D 2027-05-17 Common Stock 6250.0 3750 I By Spouse Stock Option (Right To Buy) 33.02 2029-01-21 Common Stock 112500.0 112500 D Stock Option (Right To Buy) 33.02 2029-01-21 Common Stock 25000.0 25000 D Stock Option (Right To Buy) 26.42 2024-07-31 Common Stock 30000.0 30000 D Stock Option (Right To Buy) 51.0 2025-01-02 Common Stock 10525.0 10525 D Stock Option (Right To Buy) 30.86 2026-01-03 Common Stock 16000.0 16000 D Stock Option (Right To Buy) 12.64 2026-11-16 Common Stock 2000.0 2000 D Stock Option (Right To Buy) 33.02 2029-01-21 Common Stock 6825.0 6825 I By Spouse Stock Option (Right To Buy) 18.01 2028-01-02 Common Stock 2696.0 2696 I By Spouse The Reporting Person's transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 19, 2019. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $47.75 to $48.72 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Includes 371 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2019. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $48.77 to $49.65 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $47.77 to $48.72 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $48.02 to $49.01 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $49.03 to $49.65 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $47.82 to $48.82 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $48.82 to $49.68 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. The transactions of the Reporting Person's spouse reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on November 19, 2019. Currently exerciseable. This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018. This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. This option was granted on May 17, 2017, and vests over four years, with 25% of the shares underlying the option vesting on May 8, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on August 8, 2018. This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020. This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023. This option was granted on January 4, 2016 and vests over four years, with 25% of the shares underlying the option vested on January 4, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 4, 2017. This option was granted on November 17, 2016, and vests over four years, with 25% of the shares underlying the option vesting on November 17, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on February 17, 2018. Avraham S. Adler, attorney-in-fact 2019-12-26